THU0457 Comprehensive Disease Control with Less Relapse and Radiographic Progression at One Year by Intensive Therapy with Additional Short-Course of Tocilizumab: A Real-World, Prospective Cohort Study in Chinese Patients with Rheumatoid Arthritis

X.-Y Wang,L Dai,D.-H Zheng,J.-D Ma,J Jing,L.-F Chen,Y.-Q Mo

doi:10.1136/annrheumdis-2016-eular.2509

THU0457 Comprehensive Disease Control with Less Relapse and Radiographic Progression at One Year by Intensive Therapy with Additional Short-Course of Tocilizumab: A Real-World, Prospective Cohort Study in Chinese Patients with Rheumatoid Arthritis

X.-Y Wang, L Dai + Show 5 more

https://doi.org/10.1136/annrheumdis-2016-eular.2509

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2016

Affiliation: Sun Yat-sen Memorial Hospital, Sun Yat-sen University

#csDMARDs Group #Comprehensive Disease Control + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundTocilizumab (TCZ) was the first approved non-TNFα bDMARD for rheumatoid arthritis (RA) in China since November 2013. However, the mean course of TCZ for most Chinese RA patients is about...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.